Correcting COVID-19 vaccine misinformation: Lancet Commission on COVID-19 Vaccines and Therapeutics Task Force Members.

Correcting COVID-19 vaccine misinformation: Lancet Commission on COVID-19 Vaccines and Therapeutics Task Force Members.
复制标题

纠正 COVID-19 疫苗的错误信息: 柳叶刀 COVID-19 疫苗和治疗委员会特别小组成员。

DOI:
10.1016/j.eclinm.2021.100780
复制
发表时间:
2021-03
期刊:
影响因子:
15.1
通讯作者:
Bottazzi ME
Bottazzi ME
中科院分区:
医学1区
文献类型:
--
作者:
Hotez P;Batista C;Ergonul O;Figueroa JP;Gilbert S;Gursel M;Hassanain M;Kang G;Kim JH;Lall B;Larson H;Naniche D;Sheahan T;Shoham S;Wilder-Smith A;Strub-Wourgaft N;Yadav P;Bottazzi ME

文献摘要

参考文献

被引文献

相似文献

迄今为止,已接种了超过 1 亿例新冠肺炎 (COVID-19) 疫苗,其中美国占三分之一以上(3500 万例),其次是中国(2400 万例)和欧盟(1400 万例)。 2020 年,全球和美国接受调查的人中,多达三分之一或更多的人表示,他们可能会拒绝通过紧急使用授权 (EUA) 发布的第一批​​ COVID-19 疫苗。他们的理由包括有关疫苗功效、潜在副作用或加快监管审批流程的问题。即使在医护人员中,人们也注意到对 COVID-19 疫苗犹豫不决的比例很高 [1]。另一个问题是 COVID-19 疫苗的政治化,或者非裔美国人社区中流传的与结构性种族主义和生物医学界历史经验有关的怀疑 [2, 3]。因此,虽然全球一些国家的整体疫苗信心可能会增加 [4],但 COVID-19 疫苗接种信心可能会出现相反的情况。目前,致力于反疫苗活动的组织利用对 COVID-19 疫苗的犹豫来加剧不和或质疑疫苗的功效和安全性 [5]。最终,阻止传播可能需要至少 70-80% 的疫苗覆盖率 [6]。匆忙疫苗:将全球开发 COVID-19 疫苗的努力报道为一场“竞赛”,同时将其与国家身份联系起来,或者将《星际迷航》的图像融入到美国的 COVID-19 疫苗计划中,这些都没有帮助。多年来,反疫苗游说团体的一个核心但却错误的原则是,疫苗没有经过充分的安全性测试。在美国和国际上,第 3 阶段试验是对 30,000 至 60,000 名人类志愿者进行的强有力的研究,相当于获得疫苗许可所需的其他大型疫苗临床试验 [7]。 “普通疫苗”从临床前阶段开始需要 10.7 年的时间表 [7],而 COVID-19 疫苗项目可能会在不到一年的时间内完成最终获得 EUA 的临床测试。然而,关于 COVID-19 疫苗的研究并不是在 2020 年才开始的,而是
To date, just over 100 million COVID-19 immunizations have been administered, led by the United States accounting for more than onethird (35 million), followed by China (24 million) and the European Union (14 million). In 2020, up to one-third or more of people surveyed both globally and in the United States indicated they might refuse the first COVID-19 vaccines when released through emergency use authorization (EUA). Their rationale included questions about vaccine efficacy, potential side effects, or speeding through regulatory approval processes. Even among healthcare workers, high rates of COVID-19 vaccine hesitancy were noted [1]. Another issue is the politicization of COVID-19 vaccines, or suspicions circulating in the African American community linked to structural racism and historical experiences with the biomedical community [2, 3]. Thus, while overall vaccine confidence may be increasing in some countries globally [4], the opposite might be happening regarding COVID-19 vaccination confidence. Currently, organizations dedicated to antivaccine activities exploit COVID-19 vaccine hesitancy to fuel discord or discredit vaccine efficacy and safety [5]. Ultimately, halting transmission may require at least 70À80% vaccine coverage [6]. Rushing Vaccines: Reporting global efforts to develop COVID-19 vaccines as a “race” while tying it to national identities or imbuing the US COVID-19 vaccine program with Star Trek imagery were not helpful. For years, a central but false tenet of the antivaccine lobby has been that vaccines are not adequately tested for safety. In both the US and internationally, phase 3 trials were well-powered studies of 30,000 to 60,000 human volunteers, equivalent to other large vaccine clinical trials required to license vaccines [7]. An “average vaccine” requires a 10.7-year timeline beginning with the preclinical phase [7], whereas COVID-19 vaccine programs may complete clinical testing leading to EUA in less than a year. However, the research on COVID-19 vaccines did not first begin in 2020, but
DOI: 10.1016/j.socscimed.2020.113638
发表时间: 2021-03
期刊: Social science & medicine (1982)
影响因子: --
作者:
Callaghan T;Moghtaderi A;Lueck JA;Hotez P;Strych U;Dor A;Fowler EF;Motta M
通讯作者: Motta M
DOI: 10.1371/journal.pone.0057755
发表时间: 2013-03-20
期刊: PLOS ONE
影响因子: 3.7
作者:
Pronker, Esther S.;Weenen, Tamar C.;Osterhaus, Albertus D. M. E.
通讯作者: Osterhaus, Albertus D. M. E.
DOI: 10.1016/s0140-6736(20)31558-0
发表时间: 2020-09-26
期刊: Lancet (London, England)
影响因子: --
作者:
de Figueiredo A;Simas C;Karafillakis E;Paterson P;Larson HJ
通讯作者: Larson HJ
DOI: 10.1016/j.amepre.2020.06.011
发表时间: 2020-10-01
影响因子: 5.5
作者:
Bartsch, Sarah M.;O'Shea, Kelly J.;Lee, Bruce Y.
通讯作者: Lee, Bruce Y.